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http://www.biomedcentral.com/1755-8794/5/1/19RESEARCH ARTICLE Open AccessSaliva samples are a viable alternative to blood
samples as a source of DNA for high throughput
genotyping
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Helena M Earl2,4, Paul PD Pharoah1, Alison M Dunning1 and Carlos Caldas1,2,3,4Abstract
Background: The increasing trend for incorporation of biological sample collection within clinical trials requires
sample collection procedures which are convenient and acceptable for both patients and clinicians. This study
investigated the feasibility of using saliva-extracted DNA in comparison to blood-derived DNA, across two
genotyping platforms: Applied Biosystems TaqmanTM and Illumina BeadchipTM genome-wide arrays.
Method: Patients were recruited from the Pharmacogenetics of Breast Cancer Chemotherapy (PGSNPS) study.
Paired blood and saliva samples were collected from 79 study participants. The Oragene DNA Self-Collection kit
(DNAgenotekW) was used to collect and extract DNA from saliva. DNA from EDTA blood samples (median volume
8 ml) was extracted by Gen-Probe, Livingstone, UK. DNA yields, standard measures of DNA quality, genotype call
rates and genotype concordance between paired, duplicated samples were assessed.
Results: Total DNA yields were lower from saliva (mean 24 μg, range 0.2–52 μg) than from blood (mean 210 μg,
range 58–577 μg) and a 2-fold difference remained after adjusting for the volume of biological material collected.
Protein contamination and DNA fragmentation measures were greater in saliva DNA. 78/79 saliva samples yielded
sufficient DNA for use on Illumina Beadchip arrays and using Taqman assays. Four samples were randomly selected
for genotyping in duplicate on the Illumina Beadchip arrays. All samples were genotyped using Taqman assays.
DNA quality, as assessed by genotype call rates and genotype concordance between matched pairs of DNA was
high (>97%) for each measure in both blood and saliva-derived DNA.
Conclusion: We conclude that DNA from saliva and blood samples is comparable when genotyping using either
Taqman assays or genome-wide chip arrays. Saliva sampling has the potential to increase participant recruitment
within clinical trials, as well as reducing the resources and organisation required for multicentre sample collection.Background
Incorporation of biological sample collection within clin-
ical trials and cohort studies will enhance our ability to
identify biomarkers that improve individualisation of treat-
ments. This requires sample collection procedures which
are convenient and acceptable for both patients and clini-
cians. Whilst blood sampling and tumour biopsies are* Correspondence: ja344@medschl.cam.ac.uk
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reproduction in any medium, provided the oressential in some circumstances, often a less invasive pro-
cedure is sufficient and would improve trial recruitment.
The potential advantages of saliva sample collection com-
pared with blood sample collection include lower overall
cost, lower infection risk, increased patient convenience,
acceptability, compliance and uptake. However potential
disadvantages include lower mean DNA yield and greater
contamination with bacterial DNA. This study investigates
the suitability of DNA extracted from saliva compared
with DNA extracted from blood for high-throughput
genotyping platforms.
Buccal sampling as an alternative to venous blood sam-
pling has been investigated previously, but there is still re-
luctance to using DNA extracted from saliva samples oral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 DNA yields from blood and saliva
Sample
type
Sample volume
collected
(range)/ml
Mean DNA
yield (range)/μg
Mean yield
per ml sample
collected
(range)/μg
Blood 8 (4–10) 210 (58–577) 26 (6–73)
Saliva 2* 24 (0.2 - 52) 12 (0.1 - 26)
*in 2 ml Oragene solution.
Table 3 Illumina genotype call rates (GCR)
Sample Mean SNP
calls blood DNA
Mean SNP calls
saliva DNA
1 316,954 315,527
2 316,057 310,761
3 317,271 316,657
4 314,863 312,943
Overall 316,286/318,075 (99.4%) 313,972/318,075 (98.7%)
The number of SNPs successfully genotyped/the total number SNPs
common to both Illumina HumanHap370 and HumanHap550 chips
(318,075) for the 4 samples tested.
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concerns over reduced yield and quality of DNA extracted
from saliva, especially given the rigorous DNA requirements
for high-throughput technologies. Studies investigating bac-
terial content in saliva collection samples have estimated
that the median bacterial content from Oragene saliva col-
lection kits is 11.8%, whereas bacterial content from mouth-
wash and buccal swabs was up to 60% and 90% respectively
[8]. One study (n=23), using the Illumina HumanHAP300
beadchip, concluded that under optimal conditions DNA
from buccal cells provided comparable results to blood-
derived DNA [9]. Another study successfully used saliva-
extracted DNA in a Genome Wide Association Study
(GWAS), but there was no clear comparison of the mean
DNA yield or range of DNA yield found with each sample
type. However the study did show comparable concordance
and call rates [10]. One published study in dogs compared
the performance of paired canine saliva and blood-derived
DNA using the Illumina Infinium platform. This study
demonstrated that canine saliva DNA was suitable for high-
throughput genotyping studies [11].
This study compares DNA extracted from blood and sal-
iva across two genotyping platforms. The Applied Biosys-
tems TaqmanTM platform allowed comparison of paired
saliva and blood DNA samples in 79 study participants,
while the Illumina beadchipsTM compared genotyping
quality across thousands of SNPs in four participants.
The study also compared: (i) DNA yields from normal
extraction procedures on 9 ml EDTA blood tubes (monov-
ette/vacutainer) and Oragene DNA Saliva Self-Collection
kits (DNA GenotekW) (ii) Ratios of Absorbance at 260 and
280 nm (iii) DNA fragmentation (iv) Genotype Call Rates
(i.e. the number of results obtained) for each type of DNA
and (v) Genotype Concordances between matched pairs ofTable 2 Taqman genotype call rates (GCR)
SNP Sample call rate
blood DNA
Sample call rate
saliva DNA
rs12642938 157/158 152/158
rs10028494 157/158 151/158
rs7435335 157/158 158/158
rs3924194 156/158 157/158
Overall 627/632 (99.2%) 618/632 (97.8%)
The number of samples successfully genotyped/the total number of
samples attempted, for each SNP tested.samples – a measure of the accuracy of the genotypes
obtained.
Methods
Patient samples
Paired blood and saliva samples (n= 79) were collected
from a subset of patients participating in the Pharmaco-
genetics of Breast Cancer Chemotherapy (PGSNPS) study,
which recruited patients from four UK breast cancer
chemotherapy studies [12-14]. After obtaining written,
informed consent, two EDTA blood samples (median
volume 8 ml) were initially collected from all participants.
Subsequently participants were randomly selected for
the saliva-blood feasibility study. These participants were
contacted by mail and received an information leaflet
explaining the aims and requirements of the study, a con-
sent form which the patient signed, if they wished to par-
ticipate, or alternatively a form to decline entry into the
study and a stamped addressed envelope. If the patient
consented, a trial research nurse or doctor would co-sign
the consent form, retain a copy centrally and return a copy
to the patient, enclosing the Oragene DNA Self-Collection
kit (DNA GenotekW) together with the manufacturer’s
instructions. Eighty-five percent of patients approached
regarding the saliva-blood feasibility study gave consent
and entered the study. The self-collection method did not
require the participation of a regional hospital to recruit
the patient. Patients recruited to this feasibility study
returned the samples by post or in person, over a period of
2 months from April 2008 to May 2008. Samples were
received by a nominated research nurse who stored the
samples at room temperature until the samples were
brought to the laboratory for extraction. As samples were
received at different time points, different samples will
have been stored for variable lengths of time.
The saliva-blood feasibility study received ethical ap-
proval in April 2008 from the Cambridgeshire 1 (formerly
Huntingdon) Research Ethics Committee, UK.
Saliva DNA extraction
The Oragene saliva collection device was selected for use
because at the time the study was initiated this was the
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system. DNA was extracted from a 500 μl aliquot from the
Oragene DNA/saliva Self-Collection kits in accordance
with the manufacturer’s instructions [15]. Each sample
was bar-coded, and stored until required for DNA extrac-
tion. Extracted samples were stored at −20°C prior to
genotyping. DNA was quantified using Picogreen (Invitro-
gen, Ltd), according to manufacturer’s instructions, which
specifically measures double stranded DNA, thus ensuring
more accurate measurement of the human DNA compo-
nent of total saliva DNA. All samples were normalised to
2 ng/μl, based on the Picogreen quantification, prior to
genotyping.
Blood DNA extraction
Lymphocyte DNA has been extracted and normalised to
40 ng/μl for storage by Gen-Probe, Livingstone, UK, using a
single-tube chloroform extraction procedure. Subsequently
this DNA was normalised to 2 ng/μl for genotyping
Taqman genotyping
Genotyping was performed using TaqmanW according to
manufacturer’s instructions. Primers and probes (FAM
and VIC labelled) were supplied directly by Applied Bio-
systems as Assays-by-DesignTM (see Additional file 1:
Figure S1). Saliva DNA samples were plated out in dupli-
cate on a 384 well plate, alongside additional duplicate
DNAs taken from the paired blood samples (all normal-
ised to 2 ng/μl). Plates were read on the ABI Prism 7900
using the Sequence Detection Software (Applied Biosys-
tems). Four assays, which had been previously used in
other research projects (data not shown) and therefore
known to work well, were chosen for this experiment.
Genome wide genotyping of paired blood and saliva
samples using HumanHap duo BeadChip arrays
DNA from four saliva samples was genotyped in dupli-
cate using HumanHap300 Duo Illumina BeadChip
arrays. DNA from matching blood samples was geno-
typed in duplicate using HumanHap550 Duo BeadChips.
The change in array was due to the manufacturers stop-
ping availability of HumanHap300 Duo Illumina Bead-
Chip arrays, during the period the study was conducted.
The assay was performed following manufacturer’s
instructions [16] using 750 ng of each DNA sample, nor-
malized to 50 ng/μl.
Spectrophotometry to assess DNA purity
Ten matched saliva (of varying yields) and blood samples
were assessed for A260/A280 ratio (Additional file 1:
Table S1). A 1/100 dilution was prepared (DNA/deio-
nised H20) and analysed, using a CECIL CE2041 (2000
SERIES) spectrophotometer, according to the manufac-
turers instructions.Microchip electrophoresis to assess fragmentation of DNA
Three matched saliva and blood DNA samples were
randomly selected and assessed (see Additional file 1:
Figure S2) using the Shimadzu Microchip Electrophor-
esis System and SYBRWGold nucleic acid gel stain, (2 μl
DNA in 4 μl DNA-500 Marker) according to manufac-
turer’s instructions.
Results
The yields of DNA extracted from blood and saliva, as mea-
sured by Picogreen (Invitrogen Ltd) are shown in Table 1.
We aimed to collect 2 ml of saliva and 9 ml blood from
each participant but not all provided ideal volumes. The ac-
tual volumes of saliva obtained were not recorded but ap-
proximate volumes of blood obtained from each participant
were recorded (median 8 ml, range 4–10 ml). Total DNA
yields from the saliva samples (mean 24 μg, range 0.2–
52 μg) were lower than from the blood samples (mean
210 μg, range 58–577 μg) and an approximate 2-fold differ-
ence in yield remained after adjusting for the biological
sample volume collected. However the yield from all but
one of the saliva samples was sufficient for chip genotyping
(chip genotyping protocols vary, but typically require
500 ng-1 μg DNA at concentrations of 50–100 ng/μl). The
chips used in this study each required 750 ng DNA.
The quality of the DNA obtained was assessed by sev-
eral criteria. Ratios of absorbance at 260 nm and 280 nm
are presented in Additional file 1: Table S1. In this study
DNA from blood has a mean (A260/A280 ratio) value
(1.71), very close to the ideal value of 1.8. The mean
(A260/A280 ratio) values from saliva is a little lower
(1.56), indicating more protein contamination in the sal-
iva extracted DNA. DNA fragmentation was compared
on a bio-analyser and the results are shown in Add-
itional file 1: Figure S2. Both DNA types have a clear
high molecular weight band, but a more intense band of
fragmented DNA is visible in DNA extracted from
saliva.
Genotype Call Rates (GCR) for the Taqman assays
were expressed as the proportions of DNA samples gen-
erating results in each SNP assay and for the Illumina
Beadchip assays these were the number of SNPs called
per DNA sample (Tables 2 and 3). Call rates for blood
DNA were all >99%, using both measures, and call rates
for saliva DNA were comparable (>97%). Figure 1 shows
an example Taqman genotype plots for SNP rs3924194
and illustrates that signal strength and cluster definition
are very similar for DNA from both sources.
As a further test of the quality of the DNA, we also
examined the genotype concordance between duplicate
DNA samples in which both gave a result - a measure of
the accuracy and hence reproducibility of the genotype
calling. Concordance rates were high - for Taqman geno-
typing they were all >99% and for Illumina beadchip
Figure 1 Example of Taqman Allelic Discrimination Plots for SNP rs3924194 on DNA from blood (right) and saliva (left).
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saliva DNA (Table 4 and 5).
During the course of this study, Illumina changed their
chip format such that the saliva DNA samples were geno-
typed on HumanHap300 Duo BeadChips (total 318,511
SNPs) while the matched blood DNA samples were geno-
typed on HumanHap550 Duo BeadChips (total 555,352
SNPs). We thus restricted our analyses to the 318,075 SNP
assays common to the two formats (Tables 3 and 5).Table 4 Taqman genotype concordance
SNP Matched blood DNA
rs12642938 78/78
rs10028494 78/78
rs7435335 78/78
rs3924194 77/77
Overall 311/311 (100%)
The number of concordant results/the number of samples with 2 genotype calDiscussion
These results demonstrate that saliva DNA was of compar-
able quality to blood DNA. A valid concern, prior to this
study, was that saliva may contain significant proportions
of DNA from oral bacteria and/or food. If this had been
the case, the true concentration of human DNA added to
each assay would have been below the Picogreen calculated
concentration and overall call rates would have been pro-
portionately reduced. We observed negligible evidence ofMatched saliva DNA Matched blood/saliva DNA
75/75 73/74
75/75 74/74
79/79 77/78
78/78 76/76
307/307(100%) 300/302 (99.3%)
ls for the 4 SNPs tested in 79 samples.
Table 5 Illumina genotype concordance
Sample Matched blood DNA Matched saliva DNA Matched blood/saliva DNA
1 306,737/307,301 (99.8%) 313,721/313,811 (100%) 309,996/310,351 (99.9%)
2 314,603/314,646 (100%) 316,572/316,579 (100%) 314,421/314,479 (100%)
3 315,719/315,732 (100%) 315,688/315,736 (100%) 315,675/315,707 (100%)
4 303,915/304,196 (99.9%) 313,665/313,721 (100%) 309,613/309773 (99.9%)
Overall 99.9% 100% 100%
The number of concordant results/the total number of SNPs with 2 genotype calls for the 4 samples tested on Illumina chips.
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evidence of greater protein contamination and DNA frag-
mentation in the saliva DNA.
This study has some limitations. The change in Illu-
mina chip format made our study design sub-optimal,
however, the very high concordance rates we observe be-
tween saliva and blood DNA despite the change in for-
mat demonstrate that this issue, which was beyond our
control, has not affected the conclusions of our study.
The actual volume of saliva received was not recorded.
This value would have provided an estimate of patient
compliance with manufacturers’ instructions for using
the saliva collection kit and producing the required
amount of saliva in the sample. However, the aim of this
article was to establish whether DNA of an acceptable
quality and quantity could be obtained to allow high-
throughput genotyping on different platforms, which we
have successfully demonstrated.
The results of this feasibility study have already informed
the collection of saliva samples to increase recruitment into
Pharmacogenetics of Breast Cancer Chemotherapy
(PGSNPS) study. A total of 444 saliva samples have been
collected and 19% of all the DNA samples analysed from
this study to date have been saliva derived.
Individual saliva sampling kits are more expensive than
blood sampling kits however this cost has to be counter-
balanced by the increased inconvenience to the patient and
the cost of trained staff required to obtain blood samples. In
addition commercial extraction of DNA from saliva is
cheaper than from blood (Gen-Probe extraction costs for
blood £8/sample and for saliva £5.10/sample).
Conclusions
Although DNA yield is approximately 2-fold lower from
saliva than from blood and other measures indicate slightly
lower quality DNA, the key measure of genotyping quality
is comparable on both Taqman and Illumina genome-wide
beadchip arrays platforms. Saliva collection is less invasive
than blood collection and participants who followed
printed instructions, without supervision, provided useful
quantities of DNA. The collection of saliva-derived DNA
could substantially improve recruitment to translational stud-
ies in clinical trials, reduce costs and logistical problems asso-
ciated blood collection within multicentre studies.Additional file
Additional file 1: Figure 1. Primers and probes for Taqman assays.
Figure 2 Assessment of fragmentation of 3 matched blood and saliva
derived DNA samples. Table 1 Ratio of absorbance at 260/280nm for 10
random, matched samples.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
We would like to thank: the women participating in this study and the
PGSNPS study team.
Author details
1Department of Oncology and Strangeway’s Research Laboratory, University
of Cambridge, Cambridge, UK. 2Cambridge Breast Unit and NIHR Cambridge
Biomedical Research Centre, University of Cambridge NHS Foundation
Hospitals, Hills Road, Cambridge, UK. 3Cancer Research UK Cambridge
Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK.
4Cambridge Experimental Cancer Medicine Centre, Cambridge, UK.
Authors' contributions
JEA and SI dealt with ethics applications and recruitment to the study. JEA,
MM, CC, PDPP and AD designed the study. MM and CL planned and
performed the Taqman genotyping. IS and JEA performed chip genotyping.
RR, MM and JEA completed the data analysis. AD, HME, CC, MM and JEA
drafted the manuscript. All authors read and approved the final manuscript.
Received: 28 November 2011 Accepted: 3 May 2012
Published: 30 May 2012
References
1. Freeman B, Powell J, Ball D, Hill L, Craig I, Plomin R: DNA by mail: an
inexpensive and noninvasive method for collecting DNA samples from
widely dispersed populations. Behav Genet 1997, 27(3):251–7.
2. Hayney MS, Dimanlig P, Lipsky JJ, Poland GA: Utility of a "swish and spit"
technique for the collection of buccal cells for TAP haplotype
determination. Mayo Clin Proc 1995, 70(10):951–4.
3. Le Marchand L, Lum-Jones A, Saltzman B, Visaya V, Nomura AM, Kolonel LN:
Feasibility of collecting buccal cell DNA by mail in a cohort study. Cancer
Epidemiol Biomarkers Prev 2001, 10(6):701–3.
4. Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, Parad RB, Witt D,
Klinger KW: Multiplex PCR amplification from the CFTR gene using DNA
prepared from buccal brushes/swabs. Hum Mol Genet 1993, 2(2):159–63.
5. Walker AH, Najarian D, White DL, Jaffe JF, Kanetsky PA, Rebbeck TR:
Collection of genomic DNA by buccal swabs for polymerase chain
reaction-based biomarker assays. Environ Health Perspect 1999,
107(7):517–20.
6. Walsh DJ, Corey AC, Cotton RW, Foreman L, Herrin GL, Word CJ, Garner DD:
Isolation of deoxyribonucleic acid (DNA) from saliva and forensic science
samples containing saliva. J Forensic Sci 1992, 37(2):387–95.
7. Garcia-Closas M, Egan KM, Abruzzo J, Newcomb PA, Titus-Ernstoff L, Franklin T,
Bender PK, Beck JC, Le Marchand L, Lum A, Alavanja M, Hayes RB, Rutter J,
Buetow K, Brinton LA, Rothman N: Collection of genomic DNA from
adults in epidemiological studies by buccal cytobrush and mouthwash.
Cancer Epidemiol Biomarkers Prev 2001, 10(6):687–96.
Abraham et al. BMC Medical Genomics 2012, 5:19 Page 6 of 6
http://www.biomedcentral.com/1755-8794/5/1/198. Birnboim HC, Iwasiow RM, James CMP: Human Genomic DNA Content of
Saliva Samples Collected in OrageneWDNA. Ottawa, Ontario, Canada: DNA
Genotek, Inc.; 2008.
9. Feigelson HS, Rodriguez C, Welch R, Hutchinson A, Shao W, Jacobs K, Diver WR,
Calle EE, Thun MJ, Hunter DJ, Thomas G, Chanock S: Successful genome-wide
scan in paired blood and buccal samples. Cancer Epidemiol Biomarkers Prev
2007, 16(5):1023–5.
10. Bahlo M, Stankovich J, Danoy P, Hickey PF, Taylor BV, Browning SR, The
Australian and New Zealand Multiple Sclerosis Genetics Consortium
(ANZgene), Brown MA, Rubio JP: Saliva-Derived DNA Performs Well in
Large-Scale, High-Density Single-Nucleotide Polymorphism Microarray
Studies. Cancer Epidemiol Biomarkers Prev 2010, 19:794–798.
11. Yokoyama JS, Erdman CA, Hamilton SP: Array-based whole-genome survey of
dog saliva DNA yields high quality SNP data. PLoS One 2010, 5(5):e10809.
12. Accessed at National Cancer Research Institute conference website.
http://www.ncri.org.uk/ncriconference/abstract/pdf/2007%20pdfs/B26.pdf.
13. Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA,
Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford MS, Rea DW,
Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RCF,
Twelves CJ, NEAT Investigators, SCTBG: Epirubicin and Cyclophosphamide,
Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer.
N Eng J Med 2006, 355(18):1851–62.
14. Wardley AM, Hiller L, Howard HC, Dunn JA, Bowman A, Coleman RE,
Fernando IN, Ritchie DM, Earl HM, Poole CJ: tAnGo: a randomised phase III
trial of gemcitabine in paclitaxel-containing, epirubicin/
cyclophosphamide-based, adjuvant chemotherapy for early breast
cancer: a prospective pulmonary, cardiac and hepatic function
evaluation. Br J Cancer 2008, 99(4):597–603.
15. Accessed at DNA Genotek website. http://www.dnagenotek.com.
16. Fan JB, Gunderson KL, Bibikova M, Yeakley JM, Chen J, Garcia EW, Lebruska LL,
Laurent M, Shen R, Barker D: Illumina universal bead arrays. Methods Enzymol
2006, 410:57–73.
doi:10.1186/1755-8794-5-19
Cite this article as: Abraham et al.: Saliva samples are a viable alternative
to blood samples as a source of DNA for high throughput genotyping.
BMC Medical Genomics 2012 5:19.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
